Dr. Marcel Bally, distinguished scientist, Basic and Translational Research at BC Cancer Research Institute and professor at UBC’s Department of Pathology and Laboratory Medicine, has been awarded new funding through Genome BC’s Genomics Applications Partnership Program (GAAP).
Dr. Bally’s project, A First‑in‑Class Dual‑Function siRNA to Address Limitations of Anticoagulants in Thrombotic Disease, aims to develop a novel RNA therapeutic targeting clotting‑related conditions such as thromboinflammation — a serious and prevalent complication for many patients with cancer.
In collaboration with Dr. Lih Jiin Juang of Seragene Therapeutics, Dr. Bally’s team will evaluate the safety and efficacy of this dual‑function siRNA approach, designed to address key limitations of current anticoagulant treatments.
The project is one of several BC‑GAPP initiatives supported as part of a broader $20 million federal investment in genomics‑based health innovation.
Congratulations to Dr. Bally!
Learn more about the grant and recipients in Genome BC’s announcement: BC researchers receive $8 million in federal funding to fast-track genomic solutions